endometrioid tumor


Also found in: Wikipedia.

en·do·me·tri·oid tu·mor

a tumor of the ovary containing epithelial or stromal elements resembling tumors of the endometrium.

en·do·me·tri·oid tu·mor

(en'dō-mē'trē-oyd tū'mŏr)
A tumor of the ovary containing epithelial or stromal elements resembling tumors of the endometrium.
Mentioned in ?
References in periodicals archive ?
Main adnexal type Histological subtype N (%) Nonmalignant Endometriotic cyst 56 (22.2%) n = 252 Dermoid cyst 54 (21.4%) Simple cyst 52 (20.6%) Serous cystadenoma 41 (16.3%) Mucinous cystadenoma 19 (7.5%) Tubo-ovarian abscess/salpingitis 16 (6.3%) Paraductal cyst 8 (3.2%) Ovarian fibroma 6 (2.4%) Malignant n = 50 Ovarian serous tumor 22 (44%) Ovarian endometrioid tumor 11 (22%) Ovarian serous borderline 5 (10%) Ovarian mucinous tumors 3 (6%) Ovarian clear cell tumor 3 (6%) Ovarian mucinous borderline 2 (4%) tumors Fallopian tube malignancy 2 (4%) Ovarian folliculoma 1 (2%) Ovarian sarcoma 1 (2%) Table 2: Difference in serum tumor markers among groups by the Mann- Whitney U test.
Compared with the other 2 groups, the MLH1 methylated group was associated with a higher-grade endometrioid tumor with lymphovascular invasion, and 19% had the distinctive undifferentiated histology.
The most common epithelial tumors were serous (115 cases, 47.52%), mucinous (36 cases, 14.88%), Brenner tumor (6 cases, 2.48%), and endometrioid tumor (1 case, 0.41%).
Gly-to-Asp (GGT [right arrow] GAT) mutations at codon 12 of the K-ras gene were common for two borderline tumors (one mucinous and one serous), two mucinous ovarian carcinomas, one clear cell neoplasm, one endometrioid tumor, and one nonepithelial tumor, but not for the serous ovarian carcinomas.
For the purpose of our study, if notable nuclear atypia was present and was seen in an arbitrarily set proportion of less than 10% of an endometrioid tumor, then reviewers classified the case as G2EC with focal, marked nuclear atypia.
Soslow, MD, written communication, 2013), alerting the clinician that the tumor may be a variant endometrioid tumor with loss of p53 function.
Hormone receptors ER and PR are frequently used to distinguish endometrioid and serous carcinomas and generally show strong diffuse expression in approximately 80% of FIGO 1 and 2 endometrioid tumors. The reported degree of immunoreactivity in FIGO 3 endometrioid tumor is markedly less, ranging from 15% to 50%.
Morules with optically clear nuclei in ovarian borderline endometrioid tumor. APMIS.
Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990.
Patients with synchronous endometrioid tumors of the endometrium and ovary are generally younger, tend to be of low grade, and the prognosis of endometrioid type carcinoma is better than other histological types of carcinoma.
For example, women with high-grade endometrioid tumors who are CN high were historically treated with radiotherapy but might do better treated with systemic adjuvant therapies traditionally reserved for nonendometrioid carcinomas.